PTGX
PTGX clinical trials: Protagonist Therapeutics, Inc
Every trial on ClinicalTrials.gov where Protagonist Therapeutics, Inc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 14
- Trials linked
- 13
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PTGX on the catalyst calendar · PTGX registry changes
- Primary completion Feb 21, 2025ActualPhase 3NCT05210790A Study of Rusfertide in Adults With Polycythemia Vera (PV)Protagonist Therapeutics, Inc. · Polycythemia VeraActive, not recruitingPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 29, 2026ActualPhase 1NCT07153146Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.Protagonist Therapeutics, Inc. · Healthy VolunteerCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2026Sponsor estimatePhase 3NCT06033586Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraProtagonist Therapeutics, Inc. · Polycythemia VeraActive, not recruitingPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2021ActualPhase 2NCT04202965PTG-300 in Subjects With Hereditary HemochromatosisProtagonist Therapeutics, Inc. · Hereditary HemochromatosisCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 14, 2023ActualPhase 2NCT04057040Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)Protagonist Therapeutics, Inc. · Polycythemia VeraCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2018ActualPhase 2NCT02895100Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative ColitisProtagonist Therapeutics, Inc. · Ulcerative ColitisTerminatedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2023ActualPhase 2NCT04767802PTG-300 in Patients With Polycythemia Vera and Elevated HematocritProtagonist Therapeutics, Inc. · Polycythemia VeraCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2023ActualPhase 2NCT04504383PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)Protagonist Therapeutics, Inc. · Ulcerative Colitis Chronic ModerateCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2021ActualPhase 1NCT04819620Pharmacokinetics of PN-232 in Healthy VolunteersProtagonist Therapeutics, Inc. · Healthy SubjectsCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2021ActualPhase 1NCT04621630Pharmacokinetics of PN-235 in Healthy VolunteersProtagonist Therapeutics, Inc. · Healthy VolunteersCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2021ActualPhase 1NCT04516382Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy VolunteersProtagonist Therapeutics, Inc. · Healthy VolunteersCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2020ActualPhase 2NCT03802201Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic AnemiaProtagonist Therapeutics, Inc. · β-thalassemiaCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2020ActualPhase 2NCT04054921Safety Study for Beta Thalassemia Subjects on PTG-300Protagonist Therapeutics, Inc. · β-thalassemiaCompletedPTGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 3, 2022ActualPhase 1NCT04524221PTG-100 for Patients With Celiac DiseaseNielsen Fernandez-Becker · Celiac DiseaseCompletedPTGXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 14 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner